Major Collaborative Research Agreements in Effect in Fiscal Year 2006
New CRADAs
Ongoing CRADAs
New RCAs
Ongoing RCAs
Gifts
New CRADAs
During FY 2006, NIAID scientists entered into the following four new CRADAs.
| Collaborator |
Investigator |
Title |
| BioVeris |
Lenardo, M |
Development of Novel Diagnostic Assays for Early Detection and Monitoring of Infectious and Immune Disorders in Human Using a Proprietary Electrochemiluminescence (ECL) Technology |
| IAVI |
Wynn, T
Kwong, P |
Rational Design of HIV Envelope Glycoprotein Variants for Structural and Immunological Analysis Using X-Ray Crystallography to Elicit Broadly Neutralizing HIV-1 Antibodies |
| MedImmune |
Collins, P |
Development of Live Attenuated Virus Vaccines for Respiratory Syncytial Viruses, Parainfluenza Viruses and Human Metapneumovirus |
| Merial |
Valenzuela, J |
Evaluation of a Salivary Antigen Leishmania DNA Vaccine in Dogs |
Ongoing CRADAs
In addition to the new CRADAs listed above, during FY 2005, NIAID scientists also did research under the following CRADAs:
| Collaborator |
Investigator |
Title |
| Anacor |
Barry, C |
In Vitro and In Vivo screening of Novel Antitubercular Agents. |
| BioVex |
Gomez, P |
Evaluation of HSV Vectors Encoding HIV-1 Proteins. |
| Chiron |
Lane, C |
Research and Development of IL-2 as a Treatment for HIV Infection. |
| Crucell |
Gomez, P |
Development of an Improved Recombinant Adenovirus Vector for Vaccination Against the Ebola Virus. |
| Genetics Institute |
Shevach, E |
Analysis of Gene Expression in Immunoregulatory T Cells that Co-Express the CD4 and CD25 Surface Markers. |
| GenVec |
Gomez, P |
Evaluation of Adenoviral Vectors Encoding HIV-1 Proteins. |
| GenVec |
Gomez, P |
Evaluation of Adenoviral Vectors Encoding Proteins Associated with SARS. |
| GlaxoSmithKline |
Hamilton, H
Savarese, B |
A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy of rgD/Alum/MPL vaccine in the prevention of genital herpes disease in young sexually active women (DMID#01-643) |
| Innogenetics |
Purcell, R |
Analysis of the Immune Response to Hepatitis C Virus. |
| Johnson and Johnson Research (Australia) |
Malech, H |
Genome integration site analysis following ex vivo transduction of hematopoietic stem/progenitor cells by replication incompetent retrovirus vectors |
| MacroGenetics, Inc. |
Purcell, R |
Development of Prophylactic and Therapeutic Monoclonal Antibodies to Vaccinia/Smallpox, SARS, and Anthrax. |
| Maxygen |
Miller, L
Long, C
Saul, A |
Novel, Polyspecific Malaria Vaccine Development based on PfEMP1 Using Molecular BreedingTM Directed Molecular Evolution Technologies. |
| MedImmune |
Subbarao, K |
Development of Live Attenuated Vaccines for Pandemic Influenza |
| MedImmune Vaccines |
Mann, M |
Development of a Live, Attenuated Cold-Adapted Influenza Vaccine |
| Merck |
Straus, S |
A double-blind, placebo-controlled study of the efficacy of live, attenuated Oka/Merck varicella zoster vaccine in reducing the incidence and/or severity of shingles in adults |
| Quantum Dot |
Roederer, M |
Use of Quantum Dots for Improved Cellular Classification in Flow Cytometry. |
| ReaMetrix |
Roederer, M |
Dev. Procedures to validate, reagents, assays and instrumentation for measuring immunogenicity |
| Vical |
Gomez, P |
Development and selection of research-grade plasmid DNA vectors encoding West Nile Virus (WNV) proteins and formulations for potential use as prophylactic vaccines in human and veterinary applications |
| Vical |
Gomez, P |
(EP) for Prophylactic therapeutic HIV plasmid DNA (pDNA) vaccines ["(EP)" = "Electroporation"?] |
| Wyeth Pharmaceuticals |
Curlin, G |
Preventing Childhood Mortality - An Efficacy Trial of a Pneumococcal Conjugate Vaccine in Upper and Central River Divisions, The Gambia |
New RCAs
During FY 2006, NIAID scientists entered into the following four new RCAs.
| Collaborator |
Investigator |
Title |
| Adamed |
Germain, R |
Software modeling study for tumor signaling pathways |
| Merck |
Wyatt, R |
Evaluate the ability of synthetic or recombinant peptides derived from the C-terminal region of gp41 to elicit HIV-1 neutralizing antibody responses when formulated in the context of a membrane-mimetic lipophillic system |
| Seattle Biomedical Research Institute |
Narum, D |
Cloning and Expression of Candidate Malaria Vaccine var2csa in Pichia pastoris |
| Upstate Medical University, SUNY |
Mavilio, D |
Coded PBMC samples from HIV-infected individuals, expanded CD4+ cells generated from the PBMCs |
Ongoing RCAs
In addition to the new RCAs listed above, at the end of FY 2006, NIAID scientists were doing research under the following RCA.
| Collaborator |
Investigator |
Title |
| NanoMed |
Hinnebusch, J |
Nanoparticle Vaccine for Plague |
Gifts
In FY 2006, NIAID received the following gift to support its research.
| Collaborator |
Investigator |
Title |
| Beth Israel Deaconess Hospital |
Nabel, G |
Novel Recombinant Adenovirus, plasmid DNA and mycobacteria Vector Based Vaccine for HIV-1 |
| Emory University |
Shevach, E |
FNIH Gates Grand Challenge Collaborator Grant |
| Medicines for Malaria Venture |
Desai, S |
Drugs for anti-malarial compounds using assay developed by LMVR |
back to top